Boston, Massachusetts, June 2024 – Thaminda Ramanayake has joined CureVac as the new Chief Business Officer. Thaminda will be responsible for leading business strategies and operations, driving growth, and enhancing the company’s market presence.
Thaminda’s most recent role was at Affini-T Therapeutics, where he served as the Chief Business Officer for a year. In this role, he was responsible for business development and strategy, leading key initiatives to drive growth and innovation.
Prior to that, Thaminda held various roles at Sanofi for over three years. As the Vice President, Global Head of Business Development, Oncology from January 2022 to June 2023, he led global business development initiatives. Before that, he was the Vice President, Global Head of Transactions, Global BD&L and Senior Director, Global Transactions, Global BD&L, contributing significantly to Sanofi’s strategic transactions and partnerships.
Thaminda has also served as a Strategic Advisor at Allievex Corporation and AceLink Therapeutics from 2020 to 2022, providing strategic guidance and support. At BioMarin Pharmaceutical Inc., he was the Senior Director of Business Development & Strategy from April 2018 to July 2020, where he played a pivotal role in driving business growth and strategy.
Earlier in his career, Thaminda held various roles in business development and strategy at Amgen, Grant Thornton LLP, EY, and Empire Valuation Consultants, gaining extensive experience in M&A, valuation, and strategic planning.
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company specializing in messenger RNA (mRNA) technology, with over 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical applications. The core of CureVac’s proprietary technology is the use of optimized mRNA to instruct the human body to produce its own proteins capable of combating a broad spectrum of diseases.
In July 2020, CureVac partnered with GSK to co-develop new products in prophylactic vaccines for infectious diseases, leveraging CureVac’s second-generation mRNA technology. This collaboration was later expanded to include the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies.
CureVac has built a comprehensive clinical pipeline encompassing prophylactic vaccines, cancer therapies, antibody therapies, and treatments for rare diseases. Headquartered in Tübingen, Germany, CureVac employs over 1,100 people across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
